Zenas BioPharma ZBIO
NASDAQ ZBIO
$28.55 -0.03 (-0.10%)
As of: Nov 11, 2026 · 11:54 AM EST

Zenas BioPharma (ZBIO) Non Operating Interest Expenses (2026)

Updated

Zenas BioPharma (ZBIO) recorded Non Operating Interest Expenses of $1.72 million in Q2 2026, up 367.4% from the prior quarter.

Analysis

Zenas BioPharma (ZBIO) Non Operating Interest Expenses (2026) Analysis & Trends

For FY2025, Zenas BioPharma reported Non Operating Interest Expenses of $7.33 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Zenas BioPharma 1.94 Bn 1.29 Bn - 2.06 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 2.06 Mn
Jun 30, 2026 1.72 Mn
Mar 31, 2026 368,000.00
API Access

Zenas BioPharma Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=ZBIO&period=max&api_key=YOUR_API_KEY